Brazil's National Health Surveillance Agency (ANVISA) has opened a public consultation to discuss a proposal for regulating the Regulatory Sandbox, an innovative mechanism designed to modernize the regulatory environment in the Brazilian pharmaceutical sector.
The Regulatory Sandbox is a controlled environment that allows the flexibilization of regulatory requirements for companies developing innovative health solutions. This approach, already adopted in several countries, facilitates the testing and validation of new technologies and business models without compromising product safety and efficacy.
The public consultation represents an important step in building a more agile regulatory framework aligned with sector demands. During this period, companies, associations, healthcare professionals, and other interested parties can contribute comments, suggestions, and critiques to ANVISA's proposal.
This process follows global trends in regulatory modernization, where agencies worldwide seek to balance speed in innovation approval with maintaining safety and quality standards. The initiative reinforces ANVISA's commitment to supporting the development of innovative solutions in Brazil.
The Regulatory Sandbox can benefit startups, health technology companies, and pharmaceutical product developers seeking to bring innovations to market more quickly. The regulation aims to establish clear criteria, timeframes, and safety parameters for these controlled experiments.
Participation in the public consultation is open and can be conducted through channels made available by ANVISA. The collected feedback will be essential to refine the proposal before its final implementation, ensuring that the regulation meets the needs of both the industry and the Brazilian health system.
